US firm Schering-Plough is to pay $165.0 million to settle a securities class-action law suit, which alleges that the drug major did not disclose manufacturing problems to investors. The money will go to a fund for shareholders who purchased stock in the company between May 2000 and February 2001. S-P denies any wrongdoing and claims that investors knew about the problems, which were disclosed in Securities and Exchange Commission filings, but says it will settle the case to avoid a drawn-out and costly legal battle. It adds that insurance and existing reserves will cover the payment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze